CN1649870A - 7－芳基－3,9－二氮杂双环[3.3.1]壬－6－烯衍生物及其在治疗高血压,心血管或肾疾病中作为肾素抑制剂的应用 - Google Patents

7－芳基－3,9－二氮杂双环[3.3.1]壬－6－烯衍生物及其在治疗高血压,心血管或肾疾病中作为肾素抑制剂的应用 Download PDF

Info

Publication number
CN1649870A
CN1649870A CNA038097664A CN03809766A CN1649870A CN 1649870 A CN1649870 A CN 1649870A CN A038097664 A CNA038097664 A CN A038097664A CN 03809766 A CN03809766 A CN 03809766A CN 1649870 A CN1649870 A CN 1649870A
Authority
CN
China
Prior art keywords
phenyl
diazabicyclo
alkene
ninth
racemize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038097664A
Other languages
English (en)
Chinese (zh)
Inventor
奥利维尔·贝曾康
丹尼尔·比尔
瓦尔特·菲施利
尤博斯·雷门
西尔维娅·理查德-比洛斯泰恩
汉斯－彼得·韦伯
托马斯·韦勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29286070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1649870(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1649870A publication Critical patent/CN1649870A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038097664A 2002-04-29 2003-04-08 7－芳基－3,9－二氮杂双环[3.3.1]壬－6－烯衍生物及其在治疗高血压,心血管或肾疾病中作为肾素抑制剂的应用 Pending CN1649870A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0204705 2002-04-29
EPPCT/EP02/04705 2002-04-29

Publications (1)

Publication Number Publication Date
CN1649870A true CN1649870A (zh) 2005-08-03

Family

ID=29286070

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038097664A Pending CN1649870A (zh) 2002-04-29 2003-04-08 7－芳基－3,9－二氮杂双环[3.3.1]壬－6－烯衍生物及其在治疗高血压,心血管或肾疾病中作为肾素抑制剂的应用

Country Status (26)

Country Link
US (2) US7427613B2 (enExample)
EP (1) EP1501830B1 (enExample)
JP (1) JP4041123B2 (enExample)
KR (1) KR100783863B1 (enExample)
CN (1) CN1649870A (enExample)
AT (1) ATE527261T1 (enExample)
AU (1) AU2003233963B2 (enExample)
BR (1) BR0309498A (enExample)
CA (1) CA2483241C (enExample)
CL (1) CL2003002042A1 (enExample)
CO (1) CO5631443A2 (enExample)
EC (1) ECSP045378A (enExample)
ES (1) ES2372931T3 (enExample)
HR (1) HRP20041132A2 (enExample)
IL (1) IL164767A0 (enExample)
IS (1) IS7545A (enExample)
MA (1) MA27305A1 (enExample)
MX (1) MXPA04010608A (enExample)
NO (1) NO20045042L (enExample)
NZ (1) NZ536750A (enExample)
PL (1) PL372141A1 (enExample)
RU (1) RU2343153C2 (enExample)
TW (1) TW200514786A (enExample)
UA (1) UA80821C2 (enExample)
WO (1) WO2003093267A1 (enExample)
ZA (1) ZA200408283B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109721613A (zh) * 2017-10-27 2019-05-07 四川科伦博泰生物医药股份有限公司 含季铵离子的大环酰胺化合物及其药物组合物和用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521951A1 (en) * 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
JP2006524654A (ja) * 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド 新規アザビシクロノネン誘導体
JP2006524655A (ja) * 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド ３−位にヘテロ原子を有する新規９−アザビシクロノネン誘導体
WO2004096799A1 (en) * 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd Tropane derivatives and their use as ace inhibitors
MXPA05011711A (es) * 2003-05-02 2006-01-23 Actelion Pharmaceuticals Ltd Derivados de diazabiciclononeno.
WO2004105762A1 (en) * 2003-05-30 2004-12-09 Actelion Pharmaceuticals Ltd Medical use of diazabicyclononene derivatives as inhibitors of parasite aspartic proteases
AU2004283814A1 (en) * 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd. Tetrahydropyridine derivatives
CA2540782A1 (en) * 2003-10-13 2005-05-06 Olivier Bezencon Diazabicyclononene derivatives and their use as renin inhibitors
AU2004283854A1 (en) * 2003-10-23 2005-05-06 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
US20070135406A1 (en) * 2003-12-05 2007-06-14 Olivier Bezencon Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
WO2005054243A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
CA2577084A1 (en) * 2004-08-25 2006-03-02 Olivier Bezencon Bicyclononene derivatives as renin inhibitors
WO2006021399A2 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives as renin inhibitors
WO2006021403A1 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicyclononene derivatives
WO2006021401A2 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicylononene derivatives
TW200634014A (en) * 2004-12-08 2006-10-01 Actelion Pharmaceuticals Ltd Novel diazabicyclononene derivative
WO2006063610A1 (en) * 2004-12-17 2006-06-22 Actelion Pharmaceuticals Ltd Heteroaryl substituted diazabicyclononene derivatives
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
JP4111533B1 (ja) * 2005-01-28 2008-07-02 アクテリオン ファーマシューティカルズ リミテッド 高血圧症の治療のためのレニンの阻害剤としての７−｛４−［２−（２，６−ジクロロ−４−メチルフェノキシ）エトキシ］フェニル｝−３，９−ジアザビシクロ［３．３．３１］ノン−６−エン−６−カルボン酸シクロプロピル−（２，３−ジメチルベンジル）アミド
EP1893578A2 (en) 2005-05-27 2008-03-05 Actelion Pharmaceuticals Ltd. Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
EP2420491B1 (en) 2005-12-30 2013-07-03 Novartis AG 3 , 5-substitued piperidine compounds as renin inhibitors
RU2425032C2 (ru) * 2006-02-02 2011-07-27 Актелион Фармасьютикалз Лтд Вторичные амины в качестве ингибиторов ренина
AR059886A1 (es) * 2006-03-08 2008-05-07 Actelion Pharmaceuticals Ltd Derivados de amidas como inhibidores de renina
EP2162436A4 (en) 2007-05-24 2010-08-04 Merck Frosst Canada Ltd NEW CASE OF RENININHIBITORS
SG182223A1 (en) 2007-06-25 2012-07-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
JP2010536800A (ja) 2007-08-20 2010-12-02 メルク フロスト カナダ リミテツド レニン阻害剤
NZ589019A (en) 2008-05-05 2012-10-26 Merck Frosst Canada Ltd 3, 4 - substituted piperidine derivatives as renin inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509161A (en) * 1967-07-10 1970-04-28 Boehringer & Soehne Gmbh 3-phenyl-granatene-(2)-derivatives
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
US5268361A (en) * 1991-06-07 1993-12-07 Sri International Hydroxyazido derivatives and related compounds as renin inhibitors
US5374719A (en) * 1993-06-04 1994-12-20 Eli Lilly And Company Process for converting loracarbef dihydrate to loracarbef monohydrate
KR100384979B1 (ko) 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
EP0966464B1 (en) 1997-03-03 2003-05-28 Basilea Pharmaceutica AG Substituted 2,4-diaminopyrimidines
US20060223795A1 (en) * 2003-05-02 2006-10-05 Oliver Bezencon Novel diazabicyclononene derivatives
WO2005054243A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109721613A (zh) * 2017-10-27 2019-05-07 四川科伦博泰生物医药股份有限公司 含季铵离子的大环酰胺化合物及其药物组合物和用途
CN109721613B (zh) * 2017-10-27 2021-07-30 四川科伦博泰生物医药股份有限公司 含季铵离子的大环酰胺化合物及其药物组合物和用途

Also Published As

Publication number Publication date
ATE527261T1 (de) 2011-10-15
US7427613B2 (en) 2008-09-23
ES2372931T3 (es) 2012-01-27
ECSP045378A (es) 2004-11-26
KR100783863B1 (ko) 2007-12-10
MXPA04010608A (es) 2004-12-13
KR20040101546A (ko) 2004-12-02
NZ536750A (en) 2007-02-23
JP2005527602A (ja) 2005-09-15
CL2003002042A1 (es) 2005-02-04
RU2343153C2 (ru) 2009-01-10
TW200514786A (en) 2005-05-01
AU2003233963A1 (en) 2003-11-17
EP1501830B1 (en) 2011-10-05
AU2003233963B2 (en) 2008-09-11
JP4041123B2 (ja) 2008-01-30
IL164767A0 (en) 2005-12-18
CO5631443A2 (es) 2006-04-28
US20050176700A1 (en) 2005-08-11
HRP20041132A2 (en) 2006-07-31
ZA200408283B (en) 2006-05-31
NO20045042L (no) 2004-11-19
WO2003093267A1 (en) 2003-11-13
RU2004134320A (ru) 2005-08-27
US20080312242A1 (en) 2008-12-18
BR0309498A (pt) 2005-02-15
IS7545A (is) 2004-11-22
MA27305A1 (fr) 2005-05-02
CA2483241A1 (en) 2003-11-13
PL372141A1 (en) 2005-07-11
EP1501830A1 (en) 2005-02-02
UA80821C2 (en) 2007-11-12
CA2483241C (en) 2011-05-31

Similar Documents

Publication Publication Date Title
CN1649870A (zh) 7－芳基－3,9－二氮杂双环[3.3.1]壬－6－烯衍生物及其在治疗高血压,心血管或肾疾病中作为肾素抑制剂的应用
CN1070492C (zh) 四环衍生物,制备方法和用途
CN1250545C (zh) 新的奎宁环衍生物类及含有这类衍生物的药物组合物
CN100351253C (zh) 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
CN1179945C (zh) 吲哚衍生物、其制备方法及用途
CN1264824C (zh) 喹唑啉衍生物
CN1067071C (zh) 咔啉衍生物
CN1063430C (zh) 乙醇胺衍生物
CN1280291C (zh) 用作磷酸二酯酶抑制剂的取代的吡咯并吡啶酮衍生物
CN1149214C (zh) 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
CN1533390A (zh) 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物
CN1642599A (zh) Acc抑制剂
CN1432015A (zh) 可用作细胞增殖抑制剂的被1,1－二氧代异噻唑烷取代的吲唑
CN1662527A (zh) 作为m3毒蕈碱性受体拮抗剂的吡咯烷鎓衍生物
CN1639161A (zh) 炔－芳基磷酸二酯酶－4抑制剂
CN1161334A (zh) 新的取代胍衍生物，其制备方法和其药物用途)
CN1688577A (zh) 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
CN1720047A (zh) 治疗炎性疾病的前列腺素d2受体拮抗剂
CN1496364A (zh) 取代的喹唑啉衍生物及其作为抑制剂的用途
CN1657523A (zh) 环状化合物
CN1234031A (zh) 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
CN1571786A (zh) 烷基醚衍生物或其盐
CN1329614A (zh) 稠合的哒嗪衍生物、它们的制备方法和用途
CN1151161A (zh) 稠合的咪唑化合物，它们的制备和应用
CN1913778A (zh) 趋化因子受体活性的氨基环戊基吡啶并吡嗪酮调节剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050803